Preferred Label : neisseria meningitidis, serogroup W-135;
MeSH definition : Strains of Neisseria meningitidis found mostly in Africa.;
MeSH synonym : meningococcus, serogroup w135; neisseria meningitidis, serogroup w135; meningococcus, serogroup w-135;
MeSH annotation : infection: coord IM with MENINGITIS, MENINGOCOCCAL (IM) or, if not meningitis, MENINGOCOCCAL
INFECTIONS (IM);
Origin ID : D038582;
UMLS CUI : C1136221;
ATC code(s)
Allowable qualifiers
Automatic exact mappings (from CISMeF team)
CISMeF manual mappings
Record concept(s)
See also (suggested by CISMeF)
Semantic type(s)
Strains of Neisseria meningitidis found mostly in Africa.
http://www.has-sante.fr/portail/jcms/c_2041961/fr/nimenrix-vaccins-meningococciques-a-c-w135-et-y-conjugues
http://www.has-sante.fr/portail/jcms/c_2041961/fr/nimenrix
2015
false
France
French
tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine
tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine
guidelines for drug use
meningitis, meningococcal
antibiotic therapy
evaluation of the transparency committee
insurance, health, reimbursement
vaccination
injections, intramuscular
meningococcal infections
neisseria meningitidis, serogroup a
vaccines, conjugate
neisseria meningitidis, serogroup C
neisseria meningitidis, serogroup W-135
neisseria meningitidis, serogroup y
meningococcal vaccines
meningococcal vaccines
polysaccharides, bacterial
tetanus toxoid
meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen conjugated
risk factors
infant
immunization schedule
immunization, secondary
drug interactions
child
adult
adolescent
treatment outcome
clinical trials, phase iii as topic
adaptive immunity
---
http://www.has-sante.fr/portail/jcms/c_1352587/nimenrix
http://www.has-sante.fr/portail/upload/docs/evamed/CT-12514_NIMENRIX_Insc_AVIS2_CT12514.pdf
2012
false
France
French
tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine
tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine
antibiotic therapy
evaluation of the transparency committee
insurance, health, reimbursement
vaccination
injections, intramuscular
meningococcal infections
neisseria meningitidis, serogroup a
vaccines, conjugate
neisseria meningitidis, serogroup C
neisseria meningitidis, serogroup W-135
neisseria meningitidis, serogroup y
meningococcal vaccines
meningococcal vaccines
polysaccharides, bacterial
tetanus toxoid
meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen conjugated
risk factors
infant
immunization schedule
immunization, secondary
drug interactions
child
adult
adolescent
treatment outcome
clinical trials, phase iii as topic
adaptive immunity
---
https://ansm.sante.fr/uploads/2021/03/11/aa5aecf4fd671daf296a0a493b4a765b.pdf
2010
false
France
French
antibiotic therapy
vaccination
meningococcal infections
meningitis, meningococcal
meningococcal vaccines
vaccines, conjugate
polysaccharides, bacterial
neisseria meningitidis, serogroup W-135
neisseria meningitidis, serogroup y
child, preschool
neisseria meningitidis, serogroup a
neisseria meningitidis, serogroup C
child
risk factors
treatment outcome
meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen conjugated
MenACWY-CRM vaccine
guidelines for drug use
---